<DOC>
	<DOCNO>NCT01192399</DOCNO>
	<brief_summary>The objective study assess safety efficacy eculizumab hemolytic PNH patient . In addition , pharmacokinetics ( PK ) pharmacodynamic ( PD ) response eculizumab assess compare overseas study eculizumab treatment hemolytic PNH patient .</brief_summary>
	<brief_title>C07-001 : Safety Efficacy Study Eculizumab Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Japanese individual least 12 year age Diagnosis PNH &gt; 6 month One transfusion past two year anemia anemiarelated symptom LDH level &gt; /= 1.5 x upper limit normal within 12 week Platelet count &lt; 30,000/microliters Known suspect hereditary complement deficiency History hematopoietic stem cell transplant History meningococcal disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>PNH</keyword>
	<keyword>Japan</keyword>
</DOC>